Tax alert

Ohio Supreme Court limits CAT receipts under pharma chargeback agreements

uling limits Ohio CAT to amounts realized, not unreduced invoice prices

September 25, 2026
#
State & local tax

Executive summary

Ohio Supreme Court holds CAT applies only to amounts received regardless of list price

The Ohio Supreme Court has held that a pharmaceutical manufacturer's gross receipts for purposes of the Ohio commercial activity tax (CAT) are limited to the amount actually received from drug sales and do not include invoice amounts that are never paid because of contractual chargeback arrangements.

In Perrigo Sales Corp. v. Harris (Sept. 22, 2026), the court affirmed a decision of the Ohio Board of Tax Appeals, concluding that the CAT applies to the taxpayer's actual "amount realized" from a transaction rather than a higher invoiced list price.

Although the case involves pharmaceutical distribution, its reasoning may be relevant to other businesses using contractual chargebacks, mandatory pricing offsets or similar mechanisms that establish the amount a seller is entitled to receive. Businesses can use the decision as an opportunity to compare their contracts, transaction records and CAT workpapers, identify open tax periods and assess whether their reporting reflects the economic terms of their sales The outcome will depend on the language and operation of each arrangement.


Background: Tax on chargeback amounts versus full list price

Perrigo Sales Corporation manufactures generic prescription drugs and sells them to wholesale distributors, which then sells the products to retailers like CVS or Walmart. The distributors receive invoices reflecting a wholesale acquisition cost, or list price. However, Perrigo separately negotiates pricing agreements with retailers that typically establish a lower purchase price for the products.

When distributors sell products to participating retailers, they pay Perrigo based on the lower contracted retailer price rather than the higher invoiced list price. The difference between the list price and the retailer price is referred to as a “chargeback.” According to the court, Perrigo is contractually obligated to honor these chargebacks, and approximately 97% of its distributor sales are subject to the arrangement.

Following an audit of tax years 2016 through 2018, the Ohio Department of Taxation determined that Perrigo had underreported CAT gross receipts by excluding chargeback amounts and reporting only what it had actually received. The tax commissioner asserted that Perrigo's gross receipts should equal the full list price reflected on distributor invoices. The Board of Tax Appeals disagreed, concluding that the proper measure of gross receipts was the list price less the chargeback amount, reasoning that the CAT is a tax on receipts realized by the taxpayer.

Defining “amount realized”

On appeal, the Ohio Supreme Court noted that the CAT’s statutory definition of “gross receipts” includes “total amounts realized.” The court focused on the meaning of “amount realized” and concluded that the phrase refers to the amount actually received in exchange for property sold.

The court found that Perrigo never receives the full list price reflected on distributor invoices. Instead, distributors pay Perrigo only the lower price established under retailer pricing agreements. Because Perrigo never receives the higher invoiced amount, the court concluded that the list price cannot constitute the taxpayer's “amount realized” for CAT purposes.

In reaching its decision, the court rejected the tax commissioner's argument that Perrigo was improperly deducting a business expense from gross receipts. According to the court, the chargeback was not an expense deducted after receipt of revenue. Rather, the chargeback mechanism reflected the fact that Perrigo had never realized the invoiced list price in the first place. As a result, the taxpayer's gross receipts consisted only of the amount actually paid by distributors.

Relevance to other industries utilizing chargebacks

Although the case arose in the pharmaceutical industry, the court's reasoning may have significance beyond that sector.

Businesses that utilize contractual pricing adjustments, mandatory offsets, chargeback arrangements, or other structures that affect the amount ultimately received should consider reviewing whether their CAT reporting methodology is consistent with the court's interpretation of “amount realized.” The decision may be particularly relevant where contractual arrangements establish that certain invoiced amounts will never be collected by the taxpayer.

Taxpayers with pricing, rebate, chargeback, or similar contractual arrangements should consider evaluating the impact of this decision on current and historical CAT reporting positions. The decision may provide support for taxpayers whose receipts are reduced under preexisting contractual obligations that determine the amount ultimately received from a sale. Taxpayers with questions about this decision or the Ohio CAT generally should reach out to their Ohio tax advisor.

RSM contributors

  • Brian Schneider
    Partner
  • Mark Siegel
    Mark Siegel
    Partner
  • Mo Bell-Jacobs
    Mo Bell-Jacobs
    Tax Managing Director
  • Joe Szijarto
    Senior Manager
  • Matthew Shaw
    Senior Manager

Tax resources

Timely updates and analysis of changing federal, state and international tax policy and regulation.

Subscribe now

Stay updated on tax planning and regulatory topics that affect you and your business.

Washington National Tax

Experienced tax professionals track regulations, policies and legislation to help translate changes.